SILENCE THER. (SLN)

 

SLN Share PerformanceMore

52 week high149.75 26/01/16
52 week low96.65 10/08/16
52 week change -36.15 (-26.24%)
4 week volume521,450 22/12/16

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Silence update on stake in Arrowhead Pharmaceuticals

Silence Therapeutics has issued an update to its announcement on 9 January regarding the acquisition of a minority stake ...

Minority Stake in Arrowhead Pharmaceuticals

RNS Number: 1602U Silence Therapeutics PLC 13 January 2017 Minority stake in Arrowhead Pharmaceuticals 13 th January 2017 London, 13 th January 2017 - Silence Therapeutics plc, AIM:SLN ("Silence" or the "Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, p...

Silence Therapeutics acquires minority stake in Arrowhead

Silence Therapeutics has acquired a stake, on-market, in Arrowhead Pharmaceuticals, Inc. of 6.01m shares, or 8.4% of the co...

Acquisition of Minority Stake in Arrowhead

RNS Number: 6001T Silence Therapeutics PLC 09 January 2017 Acquisition of minority stake in Arrowhead Pharmaceuticals 9 th January 2017 London, 9 th January 2017 - Silence Therapeutics plc, AIM:SLN ("Silence" or the "Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet m...

Silence Therapeutics notes Quark arbitration resolution

Silence Therapeutics has reached a settlement in the arbitration process with Quark Pharmaceuticals. Silence and its license...

Silence announces Quark arbitration resolution

RNS Number: 2913S Silence Therapeutics PLC 20 December 2016 Quark arbitration resolution 20 December 2016 London, 20 December 2016 - Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, is pleased to anno...

CRISPR/Cas9 Gene Editing Data

RNS Number: 1506P Silence Therapeutics PLC 15 November 2016 CRISPR/Cas9 Gene Editing Data A single-particle RNA based approach to in vivo CRISPR/Cas9 gene editing London, 15 November 2016 - Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment o...

Broker Forecast - Canaccord Genuity issues a broker note on Silence Therapeutics PLC

Canaccord Genuity today reaffirms its buy investment rating on Silence Therapeutics PLC (LON:SLN) and raised its price...

Fundamental DataMore

EPS-10.4
Dividend yield0 %

Latest discussion posts More

  • interesting article

    http://rnaitherapeutics.blogspot.co.uk/
    7-Jul-2014
    duringthewar
  • Re: shafted again

    o/t Thanks to all those that have supported this campaign ~~~~~ *3,717 voted so far~~~~~(That's a lot of irate investors?) Campaign to make short-selling illegal (or ...
    10-Jun-2014
    dickie3times
  • shafted again

    'I am pleased by the support of key investors at a time of heavy market volatility. I look forward to progressing Silence's pipeline with our expanded resources.' and all ...
    28-Apr-2014
    nick2name

Users' HoldingsMore

Users who hold SILENCE THER. also hold..
LLOYDS GRP.27%
BP25%
ROYAL BANK SCOT19%
BARCLAYS17%
TESCO17%

Codes & Symbols

ISINGB00B9GTXM62
SymbolsSLN, LSE:SLN, SLN.L, SLN:LN, LON:SLN, XLON:SLN